300253 Winning Health Technology Group
- 6.99
- +0.10+1.45%
Winning Health Technology Group News
Weining Health (300253): Strong profit growth rate, WINEX and WINGPT accelerate implementation
Matters: Recently, the company released its 2023 annual report and 2024 quarterly report: in 2023, it achieved revenue of 3.163 billion yuan, an increase of 2.28% over the previous year; net profit to mother was 358 million yuan, an increase of 229.4 million yuan over the previous year
Weining Health (300253): The 24Q1 profit growth rate is impressive, and strengthening repayment efforts has begun to bear fruit
The 24Q1 performance is in line with recovery expectations. The optimization of rates during the period and the strengthening of repayment efforts have begun to bear fruit. The company released its 2024 quarterly report. In 24Q1, the company achieved revenue of 490 million yuan, an increase of 10.1% over the previous year; net profit returned to mother
Weining Health (300253): “1+X” Strategy Deepens Performance Trends for the Better
Event: On April 26, 2024, the company released its 2024 quarterly report: Q1 achieved revenue of 494 million yuan, an increase of 10.09% over the previous year; net profit to mother was 166.204 million yuan, a loss of 6 for the same period last year
Southwest Securities released a research report on April 26 stating that it gave Weining Health (300253.SZ) a purchase rating, and the target price was 9.20 yuan. The main reasons for the rating include: 1) steady growth in healthcare informatization reve
Southwest Securities released a research report on April 26 stating that it gave Weining Health (300253.SZ) a purchase rating, and the target price was 9.20 yuan. The main reasons for the rating include: 1) steady growth in healthcare informatization revenue; 2) promotion of “1+X” strategy upgrade and continued implementation of the WineX benchmark; 3) forward-looking AI+ medical informatization, and the recovery of the downstream economy is worth looking forward to. (Mainichi Keizai Shimbun)
Weining Health (300253.SZ): Net profit of 166.204 million yuan for the first quarter reversed year-on-year losses
On April 26, Ge Longhui Health (300253.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 494 million yuan, up 10.09% year on year; net profit attributable to shareholders of listed companies was 166.204 million yuan, turning a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 8.6877 million yuan; basic earnings per share were 0.0077 yuan.
Weining Health (300253): WINEX large-scale delivery period has begun to accelerate profit restoration
The 2023 and 1Q24 results are in line with our and market expectations, Weining Health announced 2023 results: achieved revenue of 3.163 billion yuan, +2% year over year; net profit to mother of 358 million yuan, +230% year over year; no return
Weining Health (300253): Profit recovery clearly accelerates implementation of “1+X”
Incident: The company released its 2023 annual report, achieving operating income of 3.16 billion yuan, an increase of 2.3% over the previous year; realized net profit of 360 million yuan, an increase of 229.5% over the previous year; and realized net profit without deduction of 330 million yuan.
China Galaxy released a research report on April 22 stating that it maintains the Weining Health (300253.SZ) recommendation rating. The main reasons for the rating include: 1) the medical and health information technology business is growing steadily, and
China Galaxy released a research report on April 22 stating that it maintains the Weining Health (300253.SZ) recommendation rating. The main reasons for the rating include: 1) the medical and health information technology business is growing steadily, and losses in the innovative business sector have narrowed; 2) gross margin has increased, and the cost control effect has reached a new high level of profit per capita; 3) the “1+X” strategy continues to be upgraded, and WineX products help the hospital's digital transformation and high-quality development. (Mainichi Keizai Shimbun)
Weining Health (300253): Healthcare IT revenue rises steadily, innovative business losses narrow
Investment highlights: Incident: Weining Health released its 2023 financial report, achieving operating income of 3.163 billion yuan, an increase of 2.28% over the previous year, and net profit to mother of 358 million yuan, an increase of 229.49% over the previous year, after deducting net income from the mother
Winning Health Technology Group Co., Ltd. Just Missed Revenue By 5.6%: Here's What Analysts Think Will Happen Next
It's shaping up to be a tough period for Winning Health Technology Group Co., Ltd. (SZSE:300253), which a week ago released some disappointing full-year results that could have a notable impact on how
Guolian Securities released a research report on April 20 stating that it gave Weining Health (300253.SZ) an increase in holdings rating, and the target price was 7.26 yuan. The main reasons for the rating include: 1) the increase in the revenue share of
Guolian Securities released a research report on April 20 stating that it gave Weining Health (300253.SZ) an increase in holdings rating, and the target price was 7.26 yuan. The main reasons for the rating include: 1) the increase in the revenue share of medical information technology software sales and technical services; 2) the accelerated implementation of next-generation WineX and the release of the large vertical model WingPT; 3) loss reduction in the “Internet+Healthcare” sector. (Mainichi Keizai Shimbun)
Weining Health (300253): Profit recovery is expected to benefit from the promotion of next-generation WINEX and WINGPT
Incident: Weining Health released its 2023 annual report. In 2023, the company achieved revenue of 3.163 billion yuan, an increase of 2.28% over the previous year; net profit to mother was 358 million yuan, an increase of 229.49% over the previous year; deducted not returned to the mother
Weining Health (300253): Outstanding performance growth in 23 years, entering the WINEX batch delivery stage in 24
Profit growth was impressive in '23, and the performance in '24 is expected to recover further. The company's revenue in '23 was $3.16 billion, up 2.3% year over year. Although external regulatory activities have had a certain impact on the release of industry orders
Weining Health (300253.SZ): 2023 net profit of 358 million yuan, plans to distribute 10 to 0.2 yuan
Gelonghui, April 18 | Weining Health (300253.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 3.163 billion yuan, an increase of 2.28%; net profit attributable to shareholders of listed companies was 358 million yuan, an increase of 229.49%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 333 million yuan, an increase of 178.51% year on year; basic income per share was 0.1667 yuan; it plans to distribute a cash dividend of 0.20 yuan (tax included) to all shareholders for every 10 shares.
Weining Health (300253.SZ): Weining Health's self-developed medical model WingPT does not currently use KIMI-related technology
Gelonghui, March 21丨An investor asked Wei Ning Health (300253.SZ) on the investor interactive platform, “Does the company's self-developed WingPT use KIMI-related technology? Do the latest versions of WingPT 3.0 and KIMI have unique advantages in the field of medical information services?” The company replied that Weining Health's self-developed medical model WingPT is currently not using KIMI-related technology. The company will continue to invest in the development of WinGPT's own technology.
Weining Health (300253) Company Report: AIGC+SAAS, the leader in medical informatization, begins a new journey
Core logic: Deepening and advancing the “1+X” strategy, the WinEx series of solutions continues to be enriched, and benchmark cases are frequent. It will enter a large-scale promotion period, superimposed on the R&D and training of WingPT, an AI model in the vertical medical field, which is expected to drive the company
Express News | Weining Health: Adhere to independent research and development, accelerate core product innovation and AI scenario implementation
Express News | Galaxy Securities: Sora is a “milestone” in the development of artificial intelligence. Demand for computing power will continue to explode
Weining Health (300253.SZ): The company established a forward-looking artificial intelligence laboratory in 2017, and has invested and prepared for many years
On February 22, Ge Longhui | Wei Ning Health (300253.SZ) said during a survey of specific subjects that the key to the application of medical AI is that the model must be integrated with the medical scenario, which is not the same as the general model. The company established a forward-looking artificial intelligence laboratory in 2017, and has invested and prepared for many years. We believe that future implementation and output will mainly depend on the maturity of the downstream market.
Weining Health (300253.SZ): Overall repayment (excluding key) increased by more than 10% year-on-year in 2023
On February 22, Ge Longhui | Weining Health (300253.SZ) said during a survey by specific targets that overall repayments (excluding keys) increased by more than 10% year-on-year in 2023. Among them, repayments for long-term accounts were better than repayments under new contracts. Strengthening accounts receivable collection in 2024 is still one of the key tasks. The main measures include strong supervision (controlling each collection node), increasing incentives (such as focusing on frontline employees), and increasing the project closure rate.
Analysis
Price Target
No Data
